Skip to content
value.today

Ansa Biotechnologies, Inc.

🇺🇸 Berkeley, California, USABiotechnologyFounded 2018
Total raised
$179 M
5 rounds on record
Latest round
$54 M
Oct 2026
First round on record
Jun 2020
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Ansa Biotechnologies, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2026$54 MNo. 5$50 to $250 million

Ansa Biotechnologies, Inc.: Raise no. 5, Oct 2026

Investors in this round

18 investors had bought by the notice of Nov 18, 2026: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$54 M of $72 M offered; $18 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Lin-Arlow · Executive Officer, Director
  • Geoff Hamilton · Executive Officer
  • Jason T Gammack · Executive Officer, Director
  • Matthias Arenskotter · Executive Officer
  • Sebastian Palluk · Executive Officer
  • Brad Crutchfield · Director
  • Chenny Zhang · Director
  • Nate Cornell · Director
  • Nick Naclerio · Director
  • Yanniv Dorone · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jason T. Gammack, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 18, 2026. Read the notice at the SEC.

equitySEC
Jun 2024$46 MNo. 4$10 to $50 million

Ansa Biotechnologies, Inc.: Raise no. 4, Jun 2024

Investors in this round

41 investors had bought by the notice of Dec 10, 2025: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$46 M of $57 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel T. Lin-Arlow · Executive Officer, Director
  • Jason T. Gammack · Executive Officer, Director
  • Sebastian T. Palluk · Executive Officer
  • Chenny T. Zhang · Director
  • Matthew T. McManus · Director
  • Yanniv T. Dorone · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jason T. Gammack, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Dec 10, 2025. Read the notice at the SEC.

equitySEC
Mar 2022$68 MNo. 3$50 to $250 million

Ansa Biotechnologies, Inc.: Raise no. 3, Mar 2022

Investors in this round

28 investors had bought by the notice of May 5, 2022: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$68 M of $77 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Lin-Arlow · Executive Officer, Director
  • Sebastian Palluk · Executive Officer, Director
  • Lily Li · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daniel Lin-Arlow, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed May 5, 2022. Read the notice at the SEC.

equity, debtSEC
Oct 2021$5 MNo. 2$2 to $10 million

Ansa Biotechnologies, Inc.: Raise no. 2, Oct 2021

Investors in this round

7 investors had bought by the notice of Oct 15, 2021: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Lin-Arlow · Executive Officer, Director
  • Sebastian Palluk · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daniel Lin-Arlow, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 15, 2021. Read the notice at the SEC.

equity, debtSEC
Jun 2020$5 MNo. 1$2 to $10 million

Ansa Biotechnologies, Inc.: Raise no. 1, Jun 2020

Investors in this round

24 investors had bought by the notice of Jul 9, 2020: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $9 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, other: "Series Seed-1 Pfd Stock, Series Seed-2 Prd Stock, Series Seed-3 Pfd Stock, Series Seed-4 Pfd Stock, Series Seed-5 Pfd Stock, and Simple Agreements for Future Equity (""SAFES"") and the underlying sha
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Hillel Lin-Arlow · Executive Officer, Director
  • Sebastian Hillel Palluk · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daniel Hillel Lin-Arlow, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 9, 2020. Read the notice at the SEC.

equity, debtSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Ansa Biotechnologies, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2026).

    SEC Form D · Nov 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2026

That is all the official record says: Ansa Biotechnologies, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Ansa Biotechnologies, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 41 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Ansa Biotechnologies, Inc.
NameRoleNamed in
Daniel Lin-ArlowExecutive officerNov 2026
Geoff HamiltonExecutive officerNov 2026
Jason T GammackExecutive officerNov 2026
Matthias ArenskotterExecutive officerNov 2026
Sebastian PallukExecutive officerNov 2026
Daniel T. Lin-ArlowExecutive officerDec 2025
Jason T. GammackExecutive officerDec 2025
Sebastian T. PallukExecutive officerDec 2025
Daniel Hillel Lin-ArlowExecutive officerJul 2020
Sebastian Hillel PallukExecutive officerJul 2020
Brad CrutchfieldDirectorNov 2026
Chenny ZhangDirectorNov 2026
Daniel Lin-ArlowDirectorNov 2026
Jason T GammackDirectorNov 2026
Nate CornellDirectorNov 2026
Nick NaclerioDirectorNov 2026
Yanniv DoroneDirectorNov 2026
Chenny T. ZhangDirectorDec 2025
Daniel T. Lin-ArlowDirectorDec 2025
Jason T. GammackDirectorDec 2025
Matthew T. McManusDirectorDec 2025
Yanniv T. DoroneDirectorDec 2025
Lily LiDirectorMay 2022
Sebastian PallukDirectorMay 2022
Daniel Hillel Lin-ArlowDirectorJul 2020
Sebastian Hillel PallukDirectorJul 2020